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Abstract
It is critical that issues surrounding the abuse and misuse of prescription opioids be balanced with
the need for these medications for the treatment of pain. One way to decrease the abuse of
prescription opioid medications is to develop abuse deterrent formulations (or ADFs) that in some
way prevent drug abusers from extracting out the active ingredient in order to employ alternate
routes of administration, such as injection, snorting, and smoking. Several factors including the
pharmacokinetic profile of the drug, the features of the drug formulation that make it attractive or
unattractive for abuse, the type of drug abuser, the progression of one's addiction pathway, and
one's social environment may all play a role in the abuse of prescription opioids and what methods
are used to abuse these drugs. This paper will examine these factors in order to understand how
they affect the abuse of prescription opioids and routes of administration, and how the
development of ADFs may alter these patterns.
Introduction
The use of opioids for the management of chronic cancer
pain and for palliative care is generally accepted in today's
society, as is the use of opioids for moderate to moderate
to severe acute pain. Prescription opioid medications are
extremely effective in managing various types of pain;
nonetheless, the use of opioids to treat chronic non-can-
cer pain remains controversial mainly due to the potential
for negative impact on the patients, including abuse,
dependence, and tolerance of these substances, leading to
the under treatment of pain in many populations.
Approximately 9% of Americans suffer from chronic, non-
cancer-related pain [1]. Undertreated chronic non-cancer
pain causes significant economic, societal, and health
impacts [2], and may be related to a lack of education for
physicians about proper prescribing practices and/or fear
of being prosecuted as a result of one's prescribing pat-
terns.
A 2006 National survey on prescription opioid abuse esti-
mated that 5.2 million people in the United States used
pain relievers nonmedically in 2006 and for the first time,
prescription opioids surpasses marijuana as the drug most
often associated with drug initiation [3]. A recent study on
healthcare impacts resulting from substance abuse found
that opioid abusers were 11.2 times more likely to have
had at least one mental health outpatient visit and 12.2
times more likely to have had at least one hospital inpa-
tient stay than non-abusers and were four times more
likely to have had an emergency room visit than non-
abusers [4]. An intricate balance is crucial between mak-
ing prescription opioid medications available for appro-
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priate candidates in pain and preventing these
medications from being diverted for abuse.
Given the potential of abuse, pressure has been growing
on pharmaceutical companies to develop prescription
opioid formulations that, in some way, deter abuse and
yet, remain readily accessible for pain management. For
purposes of this manuscript, the term abuse refers to "the
intentional self-administration of a medication for a non-
medical purpose, such as altering one's state of conscious-
ness, e.g. "getting high" [5], whereas the term misuserefers
to "the use of a medication (for a medical purpose) other
than as directed or as indicated, whether willful or unin-
tentional, and whether harm results or not" [5]. It is
hoped that the development of abuse deterrent formula-
tions (ADFs) will decrease levels of abuse of prescription
opioid medications. Various types of ADFs are currently
being developed, each with a unique mechanism to
thwart abusers' attempts to manipulate the drug so that
the active ingredient is immediately available (especially
for extended release formulations) in a form conducive
for use via alternate routes of administration. Some new
formulations that aim to reduce abuse through preventing
alternate routes of administration employ physical barri-
ers that resist common methods of tampering, which
include crushing the pill, and subjecting the pill to various
chemical manipulations in order to extract the active
ingredient with the goal of preventing abuse through
intravenous, snorting, and chewing routes of administra-
tion; this type of ADF, however, would not prevent abuse
of the drug if the formulation is taken intact [6]. Antago-
nist-agonist combinations include an antagonist that
blocks the effect of the opioid if it were to be tampered
with, however, some studies have indicated that one such
formulation (Talwin®  NX; Sanofi-Aventis, Bridgewater,
New Jersey, USA) showed decreased efficacy in managing
moderate pain [7]. Although ADFs are developed with the
goal of decreasing abuse of prescription opioids though
alternate routes of administration, they will likely have lit-
tle to no impact on those who prefer to abuse these drugs
by taking the drug intact. Other drug formulations being
developed with the goal of deterring abuse include prod-
rugs, which have to be metabolized to an active form
upon ingestion to produce a pharmacological effect and
those that incorporate an aversive stimulus, such as niacin
or capsaicin, which produces an uncomfortable physical
sensation in the taker if the product is tampered with prior
to ingestion [6]. It is clear that the maximum impact of
these ADFs will most likely not be seen until, at the very
least, most of the opioid analgesics prescribed are ADFs.
What are drug abusers looking for in a 
prescription opioid?
The abuse potential of a drug is partially dependent upon
the pharmacokinetic profile of the drug, including the
chosen route of administration of the drug, how much of
the drug is administered, and the rate of onset of its effects
[8]. It is likely that the way in which abusers may be most
affected by ADFs is in regard to the route(s) of administra-
tion that are used to "get high" with a particular drug.
Routes of administration vary in the time it takes for the
drug to reach the brain; it is believed that routes of drug
administration that allow for a more rapid delivery are
associated with greater abuse liability. For the majority of
drugs, including opiates, routes of administration can be
ranked from fastest delivery method to slowest as follows:
inhalation (i.e. smoking), intravenous, intranasal, and
oral [9], although most opioids are well absorbed through
all routes of administration. Jenkins et al. (1994) showed
that although smoking heroin and administering heroin
intravenously produced detectable levels of heroin in the
blood after 1–2 minutes at similar doses, smoking pro-
duced lower blood levels than was observed for intrave-
nous administration [10]. Mansbach and colleagues
(2006) [11] indicate that: "most of the research supports
the hypothesis that a rapid rate of rise in plasma concen-
tration is more likely to result in drug liking and reinforce-
ment than a slower rise in plasma exposure" (p. S16). The
time required for a given drug, at a specific dose and route
of administration (Tmax) to achieve peak plasma concen-
trations (i.e. when Cmax is achieved) is directly related to
the reinforcement properties of the drug. Research in both
animals and humans has, in fact, shown that faster infu-
sion rates of many drugs of abuse, including cocaine [12],
nicotine [13], sedatives (i.e. pentobarbital and diazepam)
[14,15], and morphine [11], which results in higher
plasma levels of the drug, produced increased response
rates in animals and greater positive subjective effects (i.e.
"high" and drug craving) in humans than slower infusion
rates. It is likely this increase in drug blood plasma levels
(Cmax) results in the "high" or "rush" that some drug
abusers seek, possibly resulting in an increased abuse lia-
bility of the drug.
Aside from achieving rapid delivery and/or maximum
concentrations of the opioid's active ingredient in the
brain, there are a number of other factors, including how
attractive the opioid formulation is to potential abusers
and the length of time one has been abusing opioids, for
instance, that also contribute to the perceived attractive-
ness of a given opioid, which will be described in full
detail in the following sections.
The concept of opioid attractiveness
Attractiveness of a particular drug formulation may influ-
ence the extent to which a drug is abused. Previous
research has characterized the potential attractiveness of
opioids via examination of the drug's time to onset; the
method of administration, and maximum plasma con-
centrations following administration [16,17] while othersHarm Reduction Journal 2009, 6:8 http://www.harmreductionjournal.com/content/6/1/8
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have attempted to systematically examine how perceived
qualities and features of formulations contribute to a spe-
cific opioid product being viewed as more or less attractive
to those with a history of misusing/abusing this class of
drugs [18]. In this latter study, 10 factors most related to
the attractiveness of prescription opioid formulations
were identified and significant differences in the weights
attributed to the features and the corresponding factors
could be observed between those who prefer different
routes of administration (e.g., swallowing, chewing or
sucking (buccal), snorting or smoking, and injecting).
Furthermore, significant differences were found between
the different groups (which varied on preferred route of
administration) and that the model fit well for those who
preferred alternate routes of administration (i.e. injectors,
snorters, and smokers) and not for those who preferred to
take prescription opioids by swallowing. Thus, the new
abuse deterrent formulations that alter the physical and/
or chemical properties of the drug to prevent extraction
may be most likely to impact the attractiveness of that
drug for those who snort, smoke, or inject prescription
opioids.
Research using data from the ASI-MV® Connect Compo-
nent of the NAVIPPRO™ system [19] also indicates that
prescription opioids appear to have "typical" patterns of
route of administration employed by those who abuse
these drugs and are in treatment for their substance abuse
problems. That is, some drugs, such as Vicodin® or Per-
cocet®, are almost never injected, whereas other drugs,
such as morphine sulfate (e.g. MS Contin®, Kadian®, and
Avinza®), have a high rate of injection among those who
abuse them. OxyContin®, has a more "versatile" routes of
administration profile in that it is likely to be abused
through a variety of different routes as was observed in a
population of individuals seeking substance abuse treat-
ment who indicated past 30 day abuse of prescription opi-
oids (N = 4,807) at various substance abuse treatment
Routes of Administration for Various Prescription Opioids Figure 1
Routes of Administration for Various Prescription Opioids.Harm Reduction Journal 2009, 6:8 http://www.harmreductionjournal.com/content/6/1/8
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centers throughout the United States (Figure 1). Briefly,
participants for this study comprised of clients 18 years
and older attending substance abuse treatment centers
across the United States who completed the ASI-MV® Con-
nect as part of their treatment experience. The ASI-MV®
Connect is purchased by treatment facilities for efficient
and cost-effective patient evaluation and treatment plan-
ning purposes and is used as part of the standard clinical
intake to measure patients' medical, employment, drug,
legal, family and social relationships, and psychiatric
problems. For purposes of the data presented here, pre-
scription opioid use was operationalized as self-reported
past 30-day use of any prescription opioid while prescrip-
tion opioid abuse was operationalized as self-reported
past 30-day use of any prescription opioid "in a way not
prescribed by your doctor, that is, taking it for the way it
makes you feel and not for pain relief". For full details on
the sample and methods for this study, please refer to
[19].
It is clear that the route of administration profile of a drug
is very important in how some abusers view a particular
drug formulation and in patterns of abuse that are
observed. It is likely that it is an interplay of a variety of
factors that determine what routes of administration one
chooses when abusing certain drugs and that the develop-
ment of ADFs may change the patterns of behavior associ-
ated with prescription opioid abuse by making the active
ingredient less accessible and, therefore, less attractive to
those who prefer to abuse these drugs via alternate routes
of administration.
Different types of prescription opioid abusers 
and routes of administration
It is also important to note that there are different types of
prescription opioid abusers. In a seminal study, Green
and colleagues studied prescription substance abusers
entering treatment using data from the NAVIPPRO™ sys-
tem [20]. Applying latent class analysis to this data, six
classes were identified as clinically interpretable and rele-
vant subgroups of prescription opioid abusers. These
classes were labeled, based on their item-response proba-
bilities and for discussion purposes, classified as: Pre-
scribed Misusers; Healthy Abusers; Poly-prescription
Opioid Abusers Who Inject; Poly-prescription Opioid
Abusers Who Snort; OxyContin® plus Heroin Abusers; and
Methadone and Other Opioid Abusers. These classes were
distinct in their prescription opioid abuse practices and
preferences including drug preferences, reporting of pain
problems, preferred routes of administration, and socio-
demographic characteristics, among others. Three classes
of prescription opioid abusers were identified as being
injectors of opioids and/or illicit drugs and while all three
classes were characterized as injecting prescription opio-
ids and heroin, some differences exist. Poly-prescription
opioid injectors injected other drugs, including cocaine
and amphetamines, whereas those in the OxyContin® plus
Heroin group injected only heroin and used cocaine
through non-intravenous means. Furthermore, while the
Poly-prescription Opioid Injectors and the OxyContin® +
Heroin Abusers were experienced prescription opioid
abusers, those in the Methadone and Other Opioid
Abuser group were newer to prescription opioid abuse. A
stark comparison can be made between those who indi-
cate alternate routes of administration when abusing pre-
scription opioid and other drugs and those who do not, in
that the former appear to be newer to prescription opioid
abuse. Through the development of ADFs, it may be pos-
sible to influence certain types of prescription opioid
abusers, particularly those who prefer to extract the active
ingredient out of the drug formulation as to allow for
alternate routes of administration.
Natural history of opioid abuse
Another interesting component related to routes of
administration is the natural history of prescription opi-
oid abuse. In a cross-sectional study, Butler and colleagues
explored the "natural history" of prescription opioid
abuse in order to understand the different patterns that
emerge as a function of the amount of time one has
abused any opioid (i.e. prescription opioids, heroin, and/
or methadone) and one's age upon seeking treatment for
substance abuse, with respect to routes of administration,
other types of drugs abused, and the presence of problems
known to be associated with substance abuse dependence
[21]. Results from this study showed that, overall, the
longer one has abused any opioid, the more likely one is
to use alternate routes of administration (i.e. injection
and/or snorting); are more likely to abuse illicit drugs
(lifetime and/or past 30 days); and are more likely to
report problems in various areas of life functioning
according to the Addiction Severity Index (ASI). This
study also revealed that one's age also had a significant
effect on various behaviors/outcomes of drug abuse; the
younger adult population (i.e. not adolescent popula-
tion) of those seeking substance abuse treatment was
more likely to use alternate routes of administration, use
illicit drugs, and have greater problem severity as meas-
ured by the ASI. Furthermore, an interaction between
these two risk factors (length of abusing any opioid and
age) appears to exist so that the length of time abusing any
opioid and the younger one is the more likely one is to use
alternate routes of administration (i.e. injection), abuse
illicit drugs, and to experience psychological problems as
measured by the ASI. These results indicate that, in this
particular substance abuse treatment seeking population,
the younger group of prescription opioid abusers may
consist of high risk takers and the older prescription opi-
oid abusers may be more risk averse. These results may be
similar to other risk-related behaviors including thoseHarm Reduction Journal 2009, 6:8 http://www.harmreductionjournal.com/content/6/1/8
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associated with high-risk sexual behaviors. Research has
shown that a greater percentage of respondents in the
younger population (aged 18–24 years) reported having
more multiple sexual partners (21.3, range 17.0–26.4 ver-
sus 4.1, range 3.1–5.5) and had greater HIV-specific risk
factors associated with them (i.e. intravenous drug abuse,
treatment for sexually transmitted diseases during the pre-
ceding year, or a positive HIV test) (10.7, range 7.2–15.6
verses 2.6, range 1.7–4.0) than an older population (aged
35–44) [22]. A successful ADF would presumably prevent
preparation of the drug formulation for injection and
inhibit this commonly seen progression from abusing an
opioid orally to injecting it.
Routes of administration and social environment
Social environment appears to play an integral role in
determining whether a non-injecting drug user initiates
drug use via intravenous means. Research has discovered
that non-injecting users with social networks that consist
of injecting drug users (IDUs) are at a greater risk of inject-
ing [23,24]. Although most non-injecting drug users ini-
tially express negative feelings toward injection practices,
these feelings are modified by other factors including
social pressures and being associated with a group of
injectors; the lure or appeal of experimenting with injec-
tion; the notion that the drug has greater efficacy when it
is injected, and the belief that one needs to use less of it in
order to achieve the same "high" [24]. Not only do drug
abusers learn about new routes of administration from
other, more "experienced" drug abusers in their social cir-
cle, but the Internet offers a great deal of information on
routes of administration, including step-by-step instruc-
tions on how to administer drugs through various routes,
and may provide drug abusers with a discrete way of
inquiring about alternate methods of drug administration
[25]. Presumably, given a successful ADF, Internet com-
munications about the drug may still persist, but the focus
of the discussion may transition from efforts to alter the
formulation for purposes of abuse to expressions of frus-
tration about not being able to alter the formulation for
alternate routes of administration.
Drug availability
Throughout history the availability of a drug has been
shown to influence its patterns of abuse. This was demon-
strated particularly well during the heroin shortage in Aus-
tralia in 2001. Researchers noted that heroin was the most
frequently injected drug in Australia from 1996–2000,
however, in 2001, a prolonged reduction in the availabil-
ity of heroin and subsequent increase in cost occurred
[26]. Not only did heroin IDUs shift their drug of choice
to other drugs, particularly stimulants (i.e. cocaine and
methamphetamine) without a change in preferred route
of administration (i.e. heroin IDUs switched to injecting
cocaine or methamphetamine) [26-28] but there was a
drop in heroin-mediated overdoses [27] possibly due to a
decrease in the rate of heroin injection in this population
[26,28].
Research by Dasgupta et al (2008)[29] and Brownstein et
al (Submitted) indicate that there is a direct relationship
between the amount of a prescription opioid available for
medical purposes in a given geographic area and its abuse
in that area. It is presumably the case that even if it is avail-
able an abuser whose preferences are to inject or snort will
not do so with Vicodin® because of the presence of aceta-
minophen. Likewise, an abuser whose preference is to
inject oxycodone will be unlikely to try to do so if the for-
mulation he or she has available is not readily prepared
for injection. Therefore, one could predict development of
abuse deterrent opioid formulations would result in
increases in legitimate prescribed availability and appro-
priate, medical use of opioid medications without a corre-
sponding increase in reported abuse or injection of these
formulations.
Negative factors associated with illicit routes of 
administration
A critical factor in success of opioid ADFs appears to be
strongly related to their ability to decrease illicit routes of
administration, particularly intravenous drug abuse. Sev-
eral studies have indicated that a number of negative fac-
tors may be associated with illicit routes of
administration. Illicit routes of administration have been
associated with poor interpersonal relationships, work
performance, and legal problems [20]. Increased violence
has been documented among IDUs [30] as well as
increased rates of homelessness, leading to a variety of
health and societal issues [31]. Furthermore, illicit routes
of administration are linked to increased risk of non-fatal
overdose [32-34], increased risk of mortality [35,36], and
increased psychiatric comorbidity [37]. A recent report on
unintentional pharmaceutical overdose fatalities in West
Virginia showed that individuals who used diverted drugs
were more likely to use a nonmedical route of administra-
tion and to have combined prescription with illicit drugs
upon overdosing [38]. However, the increased risk of con-
tracting and subsequently transmitting blood-borne dis-
eases such as HIV, HVC, and HBV is particularly
concerning among intravenous drug users [20,39-41]. It is
possible that ADFs that can decrease alternate routes of
administration, in particular intravenous routes, may pos-
itively impact the health and functioning of those abusing
prescription opioids via alternate routes of administra-
tion, however, there still lies the possibility that intrave-
nous drug abusers will simply seek other drugs (i.e.
heroin) that are easily injected.Harm Reduction Journal 2009, 6:8 http://www.harmreductionjournal.com/content/6/1/8
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A multi-component model for understanding 
prescription opioid abuse and routes of 
administration
What determines the chosen routes of administration for
abusers of prescription opioids? Several factors including
drug formulation, drug availability, the course of an indi-
vidual's drug abuse history, one's social environment,
and/or the availability of information on how to prepare
a drug formulation for alternate routes of administration,
may be highly correlated with one another and they
appear to be some of the important determinants in what
routes of administration a drug abuser chooses. The
inverse may also be true, in that, the decisions one makes
about routes of administration may influence or be influ-
enced by the make-up of one's social network, what for-
mulation characteristics are important (i.e. having the
ability to extract the active ingredient from the drug for-
mulation), and the experience of problems associated
with drug abuse.
Formulation is only one of a number of important com-
ponents that may be relevant to routes of administration.
However, formulating a drug to make it more difficult for
an abuser to use via an illicit route may impact which
drugs an abuser chooses. It also follows that if certain pre-
ferred routes of administration are closed off to the poten-
tial abuser, that individual may choose to use an
alternative product. In the ideal circumstance, all opioid
products available for medical use would be very difficult
to abuse via illicit routes of administration.
Discussion
ADFs are unlikely to be a panacea. However, within a
broader context they may well have positive public health
effects. It is clear that a variety of factors help to determine
which routes of administration are used by individual
abusers. These factors may relate to properties of the drug
itself and/or to other personal, interpersonal, and/or soci-
etal factors. To the degree that a formulation itself may
help mitigate abuse, the ADFs could have an impact on
rates of abuse of prescription opioids. It is certainly possi-
ble that if a particular ADF employs a mechanism that pre-
vents abusers from crushing, dissolving, melting, etc., the
actual pill, then certain routes of administration will likely
be eliminated for that particular drug. However, there is
no mechanism that is going to prevent abusers from tak-
ing the drug as it was meant to be taken in excess, and
thereby still abusing the drug. The introduction of ADFs
with a certain level of difficulty added to frustrate the
extraction or tampering process may impede alternate or
unintended routes of administration and therefore, may
have benefits on public health in a variety of ways. A drug
formulation that is able to prevent a certain route of
administration (i.e. intravenous administration), that, in
an historical context, has been responsible for the trans-
mission of various blood-borne diseases, such as HIV,
HCV, and HBV, may help to decrease the transmission
rates of these illnesses. Furthermore, research has shown
that intravenous drug abuse is associated with other risky
behaviors such as polydrug abuse [42] and may indicate a
greater severity of drug dependence [43-45]. If an ADF can
be effective in making it more difficult to abuse the drug
using alternate routes of administration, a significant soci-
etal impact may include decreased healthcare costs associ-
ated with drug abuse treatment.
In any case, it is unlikely that drug formulation alone will
be sufficient to address prescription opioid misuse, abuse,
and addiction. Educational and preventive interventions,
for both patients and clinicians, will continue to play an
important role in ultimately lessening the abuse of pre-
scription opioids. Finally, the overall impact of abuse
deterrent formulations will need to await long-term epi-
demiological studies which can track the overall impact of
these drugs in comparison with other similar products
without such safeguards. It is only with such careful scien-
tific evaluation that we will learn the actual real world
impact of this new class of drugs. Nonetheless, it is con-
ceivable that ADFs can be helpful to overall efforts to
reduce prescription drug abuse and can play a valuable
role in broad scale programs focused on achieving such
reductions.
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